November 24, 2015—The Department of Health and Human Services Office of Inspector General today outlined three ways that Medicare and its beneficiaries might share safety-net healthcare providers' 340B drug discount savings. … [Read more...]
Hospitals Share Concerns About HRSA’s 340B Guidance with Congress
Changes will harm their ability to care for vulnerable patientsNovember 20, 2015—Proposed 340B drug discount policy changes – especially those affecting discharge prescriptions, physician eligibility, and infusion drugs – will jeopardize hospitals' ability to care for vulnerable patients if the government finalizes them as is, hospital leaders warned at a Capitol Hill briefing yesterday. … [Read more...]
HHS Holds Forum on Rising Drug Prices
Manufacturers say insurers and providers deserve a closer look for their roleNovember 20, 2015—U.S. Health and Human Services Secretary Sylvia Mathews Burwell today opened a forum on the high and growing cost of prescription drugs with a challenge to government agencies, pharmaceutical manufacturers, patient advocates, providers, employers, and payers to come together "to find a path that doesn’t ask us to choose between innovation and affordability." … [Read more...]
Drugmakers Seek Big Changes to 340B Mega-guidance
PhRMA and BIO say HRSA needs to do more to rein program inNovember 20, 2015—Brand-name drug and biotech companies are pleased with parts of the proposed 340B program guidance that would raise the prices hospitals pay for drugs. But in their comments to the Health Resources and Services Administration, the two main trade groups for branded drug manufacturers say the guidance doesn't go far enough. … [Read more...]
AMA Calls for Ban on Consumer Drug Advertising
Part of new policy aimed at making prescription drugs more affordableNovember 20, 2015—The American Medical Association called for a ban on direct-to-consumer advertising for prescription drugs and medical devices at the group’s annual meeting in Atlanta. … [Read more...]
Orphan Drugs Approaching 20 Percent of Pharmaceutical Sales
Recent court decision foreclosed 340B discounts for rural, cancer hospitalsNovember 11, 2015—The biopharmaceutical industry's affinity for orphan drugs keeps growing, with orphans projected to account for 20.2 percent of all prescription drug sales worldwide by 2020 – up from 11.2 percent in 2010 and 6.1 percent in 2000, a new study shows. … [Read more...]
Key Committee Chair Rep. Joe Pitts to Retire in 2016
Lawmaker has concerns about clarity of 340B program rules, oversightNovember 10, 2015—Rep. Joe Pitts (R-Pa.), the chairman of the House subcommittee with primary jurisdiction over the 340B program, is retiring from Congress when his current term ends in 2016. … [Read more...]